Yuxiong Wang

Yuxiong Wang

Auto-generated profile, based on publicly available information

Yuxiong Wang

Department of Urology Il, The First Hospital of Jilin University, Changchun, China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 December 2022 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
GZGuoqiang Zeng
Guoqiang Zeng
XLXiaojie Liu
Xiaojie Liu
XSXiaochen Su
Xiaochen Su
YWYuxiong Wang
Yuxiong Wang
BLBin Liu
Bin Liu
FLFaping Li
Faping Li
Targeted gene therapy has shown durable efficacy in non-neoplastic and neoplastic patients. Therefore, finding a suitable target has become a key area of research. Mesenchyme homeobox 1 (MEOX1) is a transcriptional factor that plays a significant role in regulation of somite development. Evidence indicates that abnormalities in MEOX1 expression and function are associated with a variety of pathologies, including non-neoplastic and neoplastic diseases. MEOX1 expression is upregulated during progression of most diseases and plays a critical role in maintenance of the cellular phenotypes such as cell differentiation, cell cycle arrest and senescence, migration, and proliferation. Therefore, MEOX1 may become an important molecular target and therapeutic target. This review will discuss the current state of knowledge on the role of MEOX1 in different diseases.

27 August 2024 in Cell Communication and Signaling
Verified
Journal Article
Open access
PDF file
YLYunkuo Li
Yunkuo Li
YPYujie Pan
Yujie Pan
XYXiangzhe Yang
Xiangzhe Yang
YWYuxiong Wang
Yuxiong Wang
BIN LIUBIN LIU
BIN LIU
FLFaping Li
Faping Li
Non-muscle myosin heavy chain IIA (MYH9), a member of the non-muscle myosin II (NM II) family, is widely expressed in cells. The interaction of MYH9 with actin in the cytoplasm can hydrolyze ATP, completing the conversion of chemical energy to mechanical motion. MYH9 participates in various cellular processes, such as cell adhesion, migration, movement, and even signal transduction. Mutations in MYH9 are often associated with autosomal dominant platelet disorders and kidney diseases. Over the past decade, tumor-related research has gradually revealed a close relationship between MYH9 and the occurrence and development of tumors. This article provides a review of the research progress on the role of MYH9 in cancer regulation. We also discussed the anti-cancer effects of MYH9 under special circumstances, as well as its regulation of T cell function. In addition, given the importance of MYH9 as a key hub in oncogenic signal transduction, we summarize the current therapeutic strategies targeting MYH9 as well as the ongoing challenges.

7 October 2020 in Journal of International Medical Research
Verified
Journal Article
Open access
PDF file
YWYuxiong Wang
Yuxiong Wang
YWYuantao Wang
Yuantao Wang
MFMingliang Feng
Mingliang Feng
XLXin Lian
Xin Lian
YLYongsheng Lei
Yongsheng Lei
HZHonglan Zhou
Honglan Zhou
Renal cell carcinoma (RCC) associated with Xp11.2 translocation/transcription factor E3 (TFE3) gene fusion is a rare and independent subtype of RCC included in the classification of MiT (microphthalmia-associated transcriptional factor) family translocation RCC. Herein, we report an adult case of Xp11.2 translocation RCC, and review the relevant literature to improve our understanding of the pathogenesis, epidemiology, clinical manifestations, diagnosis, differential diagnosis, treatment, and other aspects of the disease.